Company profile: HemoGenyx Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of cell-based and antibody immunotherapies for blood diseases. Offerings include HEMO-CAR-T, a modified T-cell therapy for Acute Myeloid Leukemia (AML); CDX, a bispecific monoclonal antibody for relapsed/refractory AML and conditioning for bone marrow transplantation; and CBR, an immunotherapy platform to prevent and combat viral infections and certain cancers, with proof of concept for SARS-COV-2.
Products and services
- CDX: A bispecific monoclonal antibody that treats relapsed/refractory AML and is used for conditioning for bone marrow transplantation
- HEMO-CAR-T: A cell-based immunotherapy for treating Acute Myeloid Leukemia (AML) using modified T cells to recognize and kill cancer cells
- CBR: An immunotherapy platform aimed at preventing and combating viral infections and certain cancers, with proof of concept achieved for SARS-COV-2
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to HemoGenyx Pharmaceuticals
CytoSen
HQ: United States
Website
- Description: Provider of natural killer (NK) cell therapeutics focused on advancing effective, expedient, and accessible NK cell therapy to fight cancer for patients and providers across a wide range of points of care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoSen company profile →
Medistem
HQ: United States
Website
- Description: Provider of adult stem cell-based therapeutic products through development, acquisition, and commercialization. Founded in 2005, the company holds 16 families of patent applications, has numerous scientific publications, and generates revenue by out-licensing certain technologies. Main candidate: Endometrial Regenerative Cell (ERC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medistem company profile →
RepliCel Life Sciences
HQ: Canada
Website
- Description: Provider of regenerative medicine developing autologous cell therapies and a dermal injector. Products: RCH-01 for androgenetic alopecia (dermal sheath cup cells); RCT-01 for chronic Achilles tendinopathy (non-bulbar dermal sheath cells); RCS-01 to rejuvenate aging and sun-damaged skin (non-bulbar dermal sheath cells); and DermaPrecise, a programmable depth and volume injector with interchangeable needle heads and built-in numbing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RepliCel Life Sciences company profile →
Coeptis Therapeutics
HQ: United States
Website
- Description: Provider of cell therapy platforms: SNAP-CAR uses monoclonal antibodies with benzyl guanine linkers for tunable oncology or autoimmune treatment; GEAR-NK is a modified NK therapy co-administered with targeted antibodies; cord blood-derived HSPCs generate NK cells; and an unmodified NK program enables allogeneic therapy without HLA matching, currently in Phase 1 for anti-viral treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coeptis Therapeutics company profile →
Angioblast
HQ: United States
Website
- Description: Provider of biotechnology therapeutic products targeting cardiovascular diseases, developing and commercializing adult stem cell therapies, protein therapeutics, gene silencing solutions, small molecule peptides and antibodies, cytokines and antigen-receptor inhibitors, DNAzymes, and MPC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angioblast company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for HemoGenyx Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to HemoGenyx Pharmaceuticals
2.2 - Growth funds investing in similar companies to HemoGenyx Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for HemoGenyx Pharmaceuticals
4.2 - Public trading comparable groups for HemoGenyx Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →